Pérez Ruiz, MargaritaBos, Mats teFernández García, PatriciaManuel, Cristina deMorales Tirado, AnaLópez Neyra, AlejandroRuiz de Valbuena, MartaRubio Alonso, MargaritaSanz Santiago, Verónica2025-10-202025-10-202025Pérez-Ruiz, M., Te Bos, M., Fernández-García, P., Manuel, C. D., Morales-Tirado, A., López-Neyra, A., Valbuena, M. R. D., Rubio, M., & Sanz-Santiago, V. (2025). Evaluation of the impact of elexacaftor/tezacaftor/ivacaftor on aerobic capacity in children with cystic fibrosis aged 6–11 years: Actual observations and clinical perspectives. Archivos de Bronconeumología, S0300289625000717. https://doi.org/10.1016/j.arbres.2025.02.0100300-2896https://hdl.handle.net/11268/16408Cystic fibrosis causes exercise limitation due to impaired lung function and other complications, which in turn increases the chance of mortality. CFTR modulators, particularly the elexacaftor/tezacaftor/ivacaftor (ETI) combination, improve lung function in children older than 6 years in real-life studies. This study aimed to assess the impact of ETI on aerobic capacity in children with CF aged 6–11 years under real-life conditions and to evaluate whether prior CFTR modulator treatment affects these outcomes.engSin licencia Creative CommonsNiñoFibrosis QuísticaCalidad de vidajournal article10.1016/j.arbres.2025.02.010open accessSaludAparato respiratorioSalud materno-infantilGoal 3: Ensure healthy lives and promote well-being for all at all ages